|
|
NK-92MI
|
|
|
ZelleRx Corporation
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension, multicell aggregates
|
|
|
Homo sapiens (human)
|
|
|
lymphoblast
|
|
|
Disease: malignant non-Hodgkin's lymphoma
Cell Type: natural killer cell; NK cell;
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
50 years
|
|
|
male
|
|
|
Caucasian, White
|
|
|
ATCC complete growth medium: The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; horse serum to a final concentration of 12.5%; fetal bovine serum to a final concentration of 12.5%.
Temperature: 37.0°C
Vessels with plug-seal caps must be used to prevent evaporation of the culture medium. When using vessels with plug-seal caps, gas the headspace of the vessels with 5% ± 1% CO2. Either a standard incubator or a 5.0% ± 1.0% CO2 incubator may then be used.
|
|
|
Protocol: CRL-2408 cell aggregates must be dispersed every 2 to 3 days by pipetting up and down on the back of the flask to produce a single cell suspension. Cell counts should be performed every 2 to 3 days to determine the viable cell density.Centrifugation and replacement of culture medium may be performed if needed to achieve the appropriate cell density.Maintain cell density between 2 X 10 (5) and 1 X 10 (6) viable cells/ml.
|
|
|
Freeze medium: FBS, 90%; DMSO, 10%
Storage temperature: liquid nitrogen vapor phase
|
|
|
recommended serum:ATCC 30-2020
recommended serum:ATCC 30-2040
parental cell line:ATCC CRL-2407
|
|
|
38894: Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260
38969: Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666
40184: Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052
|
